Day: February 10, 2021

PRESS RELEASE DATED FEBRUARY 10, 2021FILING OF THE DRAFT OFFER DOCUMENT RELATING TO THE SIMPLIFIED TENDER OFFER FOR THE SHARES OFNATIXISinitiated by the companyBPCEPRESS RELEASE RELATING TO THE FILING OF A DRAFT OFFER DOCUMENT PREPARED BY BPCE S.A. TERMS OF THE OFFER:€4.00 per share of Natixis (dividend coupon attached)OFFER PERIOD:20 trading daysThe timetable for the simplified tender offer referred to herein (the “Offer”) will be set out by the Autorité des marchés financiers (the “AMF”) in accordance with provisions of its General Regulation.  AMFThis press release (the “Press Release”) was prepared and made available to the public pursuant to Article 231-16 III of the AMF’s General Regulation.This Offer and the draft Offer document filed today with the AMF (the “Draft Offer Document”) remain subject to AMF’s review.  IMPORTANT NOTICEIn...

COMMUNIQUÉ DU 10 FÉVRIER 2021DÉPÔT DU PROJET DE NOTE D’INFORMATION RELATIVE À L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉNATIXISinitiée par la sociétéBPCECOMMUNIQUÉ RELATIF AU DÉPÔT D’UN PROJET DE NOTE D’INFORMATION ÉTABLI PAR BPCE S.A. PRIX DE L’OFFRE :4,00 euros par action Natixis (dividende attaché)DURÉE DE L’OFFRE :20 jours de négociationLe calendrier de l’offre publique d’achat simplifiée (l’« Offre ») sera déterminé par l’Autorité des marchés financiers (l’« AMF ») conformément aux dispositions de son règlement général.  AMFLe présent communiqué (le « Communiqué ») a été établi et est diffusé en application des dispositions de l’article 231-16 III du règlement général de l’AMF.            L’Offre et le projet de note d’information déposé ce jour auprès de l’AMF (le « Projet de Note d’Information ») restent...

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). These data were previously presented as part of a corporate update on Saturday, November 14, 2020.Oral Presentation Title: Intravitreal Gene Therapy for Exudative AMD and Diabetic RetinopathyDate and Time: Saturday, February 13, 2021 at 9:30 am ETSession V: Gene Therapy for Exudative AMD and Diabetic RetinopathyPresenter: Arshad M. Khanani, M.D., M.A., Director of Clinical Research, Sierra...

ERYTECH to Present at the 2021 BIO CEO &Investor ConferenceLyon (France) and Cambridge, MA (U.S.), February 10, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings. The conference will be held virtually this year with all participants joining remotely from February 16  to 18, 2021.Beginning February 16, a pre-recorded presentation by company management will be available foron-demand viewing by registered attendees anytime through March 14th by accessing the BIO CEO Conference portal. For more information...

ERYTECH tiendra une présentation à l’occasiondu BIO CEO & Investor Conference 2021Lyon (France) et Cambridge, MA (États-Unis), le 10 février 2021 – ERYTECH Pharma (Nasdaq & Euronext : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, annonce aujourd’hui que son Directeur Général, Gil Beyen, tiendra une présentation corporate de la société à l’occasion de la BIO CEO & Investor Conference 2021 et participera à des rencontres individuelles avec des investisseurs. La conférence se tiendra virtuellement cette année et tous les participants se joindront à distance du 16 au 18 février 2021.À partir du 16 février, une présentation préenregistrée par le management d’Erytech sera disponible à la demande pour les participants...

(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) —Listing market: Euronext GrowthISIN code: FR0010425595About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving...

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)NEW YORK, 10 févr. 2021 (GLOBE NEWSWIRE) —Place de cotation : Euronext GrowthCode ISIN : FR0010425595À propos de CellectisCellectis développe les toutes premières immunothérapies allogéniques fondées sur des cellules CAR-T, inventant le concept de cellules CAR-T ingéniérées sur étagère et prêtes à l’emploi pour le traitement de patients atteints de cancers. En capitalisant sur ses 21 ans d’expertise en ingénierie des génomes, sur sa technologie d’édition du génome TALEN® et sur la technologie pionnière d’électroporation PulseAgile, Cellectis développe des produits candidats innovants en utilisant la puissance du système immunitaire pour cibler et éliminer les cellules cancéreuses.Dans le cadre de son engagement dans la recherche de thérapies contre le...

MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) — BlueLinx Holdings Inc. (NYSE: BXC), a leading distributor of building and industrial products in the United States, will issue fourth quarter and full year 2020 financial results after the market closes on Wednesday, March 3, 2021. A conference call to discuss the Company’s fourth quarter and full year results will be hosted by Mitch Lewis, President and Chief Executive Officer, and Kelly Janzen, Senior Vice President and Chief Financial Officer, on Thursday, March 4, 2021, at 10:00 AM ET. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of the BlueLinx website at http://bluelinxco.com/webcast-presentations, and a replay of the webcast will be available at the same site shortly after the webcast is complete.To...

 Fourth quarter comparable store sales increase of 11.2%, full-year increase of 10.9%27% increase in fourth quarter diluted earnings per share to $5.40, full-year increase of 32% to $23.53Full-year net cash provided by operating activities increased $1.13 billion, or 66.0%, to $2.84 billionSPRINGFIELD, Mo., Feb. 10, 2021 (GLOBE NEWSWIRE) — O’Reilly Automotive, Inc. (the “Company” or “O’Reilly”) (Nasdaq: ORLY), a leading retailer in the automotive aftermarket industry, today announced record revenue and earnings for its fourth quarter ended December 31, 2020. The results represent 28 consecutive years of comparable store sales growth and record revenue and operating income for O’Reilly since becoming a public company in April of 1993.4thQuarter Financial ResultsGreg Johnson, O’Reilly’s CEO and Co-President, commented, “We are extremely...

REGINA, Saskatchewan, Feb. 10, 2021 (GLOBE NEWSWIRE) — Information Services Corporation (TSX:ISV) (“ISC” or the “Company”) is pleased to announce it has been named to the list of Saskatchewan’s Top Employers for 2021. This is the 13th consecutive year that ISC has been recognized in the provincial competition.Saskatchewan’s Top Employers is a special designation that recognizes Saskatchewan employers that lead their industries in offering exceptional places to work. Employers throughout Saskatchewan were evaluated by the editors at Canada’s Top 100 Employers using the same criteria as the national competition: (1) Physical Workplace; (2) Work Atmosphere & Social; (3) Health, Financial & Family Benefits; (4) Vacation & Time Off; (5) Employee Communications; (6) Performance Management; (7) Training...